A/S, a global healthcare company specializing in diabetes care and other chronic conditions, has been at the forefront of the rapidly expanding GLP-1 market. With a market capitalization of $376.79 ...

Amycretin, a novel once-weekly subcutaneous GLP-1 and amylin receptor agonist, was safe compared with other incretin-based ...

But generally speaking, investors can have confidence in mega-cap stocks with a dominant position within their industry. As Silicon Valley entrepreneur Peter Thiel once wrote, "Competition is for ...

With new drug development, a significant increase in sales, and high potential with Mounjaro and Zepbound, here’s what we think of Eli Lilly’s stock ...

The Danish Parliament has decided to pause the future Danish Parliament project due to a lack of broad support among political parties, and the high economic cost. The project, which aimed to restore ...